From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
Why qPCR Became the Frontline Tool in Early Cancer Diagnostics
qPCR (RT-qPCR) to monitor minimal residual disease (MRD) in chronic myeloid leukemia (CML) by quantifying BCR-ABL fusion transcripts—a breakthrough that established a new gold standard for precision monitoring in hematologic malignan- cies.¹ This use case became a model for how qPCR could deliver precise, real-time insights into disease burden and treatment response. As cancer diagnostics evolved, qPCR found broader applications in solid tumors, guiding targeted therapies by detecting mutations such as EGFR in non-small cell lung cancer, KRAS in colorectal cancer, and BRAF in melanoma ( Figure 1 ). These advances laid the ground- work for qPCR’s integration into FDA-approved companion diagnostics, where it remains a gold standard for rapid, actionable mutation detection. By enabling precise, gene-level mutation detection, qPCR laid the groundwork for molecular stratifica- tion, targeted therapies and real-time monitoring
S ince its introduction in the early 1990s, and reliable method to detect and quantify nucleic acids. It reshaped clinical diagnostics—first enabling rapid infectious disease detection, then extending into oncology as one of the earliest tools to identify cancer-related genetic mutations. A significant early application of qPCR in oncology was the use of reverse transcription quantitative PCR (qPCR) transformed molec- ular biology by providing a fast, sensitive,
cobas ®
Figure 1 . Key early oncology milestones.
GENengnews.com | 21
Powered by FlippingBook